Neprilysin (Nep) is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neprilysin (NEP; also known as neutral endopeptidase, CD10, enkephalinase, or membrane metalloendopeptidase MME) is a type II transmembrane zinc-dependent metalloprotease that serves as the dominant [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- (Abeta)-degrading enzyme in the brain. Originally characterized in the 1970s for its role in inactivating enkephalins and other neuropeptides, NEP has emerged as a central figure in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (AD) research since the landmark discovery by Iwata et al. (2000) that it is the principal enzyme responsible for [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- catabolism in vivo (Iwata et al., 2000). NEP expression and activity decline with aging and are significantly reduced in AD brains, contributing to the accumulation of neurotoxic [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- peptides. This progressive enzymatic deficit has made NEP a compelling therapeutic target for strategies aimed at enhancing [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance.
Neprilysin (NEP), also known as CD10 or membrane metalloendopeptidase (MME), is a zinc-dependent metalloprotease that plays a critical role in the degradation of the [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- (Aβ) peptide in the brain. Originally characterized for its role in peptide hormone metabolism, NEP has emerged as a key therapeutic target for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- due to its ability to degrade and clear Aβ from the brain [1][2].
NEP is a type II transmembrane protein expressed primarily in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and other [cell types[/[cell-types[/[cell-types[/[cell-types[/[cell-types[/[cell-types[/[cell-types[/[cell-types[/cell-types throughout the body. In the brain, NEP is localized to presynaptic terminals and is particularly abundant in regions affected by [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- pathology, including the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- [3].## Enzyme Structure
Neprilysin is a 750-amino acid type II integral membrane glycoprotein encoded by the MME gene on chromosome 3q25.2. Its domain organization comprises a short N-terminal cytoplasmic tail (27 residues), a single-pass transmembrane domain (23 residues), and a large extracellular catalytic domain (~700 residues) containing 12 conserved cysteine residues forming 6 disulfide bonds.
The active site is built around the conserved metalloprotease HEXXH motif (His-583-Glu-584-Xaa-Xaa-His-587), where the two histidine residues coordinate the catalytic zinc ion. A third zinc ligand is provided by Glu-646 in the downstream EXXAD consensus sequence. Glu-584 polarizes a water molecule coordinated to the zinc, which performs nucleophilic attack on the scissile peptide bond. NEP cleaves peptides at the amino side of hydrophobic residues, accommodating substrates up to approximately 3-5 kDa (Moss et al., 2020; Oefner et al., 2000).
NEP degrades a broad range of bioactive peptides, reflecting its diverse physiological roles beyond [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance:
| Substrate | Molecular Weight | Biological Function | Cleavage Efficiency |
|---|---|---|---|
| Abeta40 | 4.3 kDa | Amyloidogenic peptide in AD | High (primary [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- degrader) |
| Abeta42 | 4.5 kDa | Most aggregation-prone [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- species | High (multiple cleavage sites) |
| Met-enkephalin | 0.6 kDa | Endogenous opioid, analgesia | Very high (originally defining substrate) |
| Leu-enkephalin | 0.6 kDa | Endogenous opioid, analgesia | Very high |
| Substance P | 1.3 kDa | Nociception, [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- | High |
| Atrial natriuretic peptide (ANP) | 3.1 kDa | Blood pressure regulation, natriuresis | High |
| Brain natriuretic peptide (BNP) | 3.5 kDa | Cardiac function, vasodilation | High |
| Bradykinin | 1.1 kDa | Vasodilation, inflammation, pain | Moderate |
| Endothelin-1 | 2.5 kDa | Vasoconstriction | Moderate |
| Somatostatin | 1.6 kDa | Neuromodulation, hormone regulation | Moderate |
| Glucagon | 3.5 kDa | Glucose metabolism | Moderate |
NEP cleaves [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- at multiple internal peptide bonds (positions 4-5, 11-12, 13-14, 33-34, and others), generating fragments that are non-amyloidogenic and rapidly cleared. Importantly, NEP degrades both monomeric [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- and small oligomeric species, positioning it as a first line of defense against [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- accumulation at synapses (Shirotani et al., 2001).
| Substrate | Biological Function |
|---|---|
| [Amyloid[/entities/amyloid (Aβ[/entities/amyloid (Aβ[/entities/amyloid (Aβ[/entities/amyloid (Aβ[/entities//entities/amyloid (Aβ[/entities//entities//entities/amyloid (Aβ[/entities//entities//entities//entities/amyloid (Aβ[/entities//entities//entities//entities//entities/amyloid (Aβ](/entities//entities//entities//entities//entities/amyloid (Aβ) | Primary AD-relevant substrate |
| Substance P | Neuropeptide, pain transmission |
| Enkephalins | Endogenous opioids |
| Bradykinin | Inflammatory mediator |
| Oxytocin | Social bonding, labor |
| Vasopressin | Water retention, social behavior |
| Atrial natriuretic peptide | Blood pressure regulation |
Multiple proteases contribute to [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- catabolism in the brain. NEP is the dominant [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---degrading enzyme, but others play complementary roles:
| Feature | Neprilysin (NEP) | [Insulin-Degrading Enzyme[/entities/[insulin-degrading-enzyme[/entities/[insulin-degrading-enzyme[/entities/[insulin-degrading-enzyme[/entities/[insulin-degrading-enzyme--TEMP--/entities)--FIX-- ([IDE[/genes/[ide[/genes/[ide[/genes/[ide[/genes/[ide--TEMP--/genes)--FIX-- | Endothelin-Converting Enzyme (ECE-1) | Matrix Metalloproteinases (MMP-2, -9) |
|---|---|---|---|---|
| Enzyme class | Zinc metalloendopeptidase (M13) | Zinc metalloendopeptidase (M16) | Zinc metalloendopeptidase (M13) | Zinc-dependent endopeptidases |
| Localization | Membrane-bound, presynaptic | Cytosolic and membrane-associated | Membrane-bound, endosomal | Secreted (extracellular) |
| [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- species preference | Both Abeta40 and Abeta42; insoluble > soluble | Soluble monomeric [Abeta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- preferentially | Abeta40 > Abeta42 | Abeta40 and Abeta42 fibrils |
| Substrate size limit | <5 kDa | <10 kDa (large internal cavity) | <5 kDa | Variable (can cleave large substrates) |
| Change in AD brain | Significantly decreased | Unchanged activity; increased mRNA (compensatory) | No significant change | No significant change |
| Correlation with Abeta load | Strong inverse correlation | Weak or absent | Absent | Absent |
| Knockout mouse phenotype | Increased Abeta, impaired cognition | Modestly increased Abeta | Increased Abeta40 | Mild effects |
Miners et al. (2008) demonstrated that among the major Abeta-degrading enzymes, only NEP expression correlated significantly with Abeta accumulation and clinical diagnosis of AD, supporting its primacy in Abeta metabolism (Miners et al., 2008).
NEP is localized predominantly to the presynaptic terminal membrane, positioning it to degrade Abeta at its primary site of generation. Iwata et al. (2004) demonstrated that virally delivered NEP is axonally transported to presynaptic sites through afferent projections, confirming the functional importance of this localization for Abeta clearance along neuronal circuits (Iwata et al., 2004).
Regional brain expression is highest in the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--, followed by [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- (CA1, dentate gyrus), cerebral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- (temporal and frontal), and [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--. The [brain regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/brain-regions most vulnerable to AD -- [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and association [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- -- show the steepest age-related NEP declines, creating a permissive environment for Abeta accumulation where it causes the most damage.
NEP levels and enzymatic activity decrease progressively with normal aging in multiple species including Drosophila, mice, rats, and humans. In the human [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, NEP activity declines by approximately 25-50% between the ages of 60 and 90. [This age-related decline correlates temporally with the progressive accumulation of Abeta that begins decades before clinical AD onset, suggesting that declining NEP function is an upstream contributor to sporadic AD pathogenesis (Caccamo et al., 2005).
NEP mRNA, protein, and enzymatic activity are reduced in AD brain tissue versus age-matched controls, with the most pronounced reductions in [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and temporal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--. The inverse correlation between NEP activity and Abeta42 levels supports a causal relationship between NEP deficiency and amyloid accumulation.
The foundational studies by Iwata and colleagues established NEP's importance through genetic ablation experiments. NEP-deficient ([Mme[/genes/[mme[/genes/[mme[/genes/[mme[/genes/[mme--TEMP--/genes)--FIX---/-) mice show significantly elevated brain Abeta levels, with both soluble and oligomeric species increased, leading to impaired synaptic plasticity and cognitive deficits even without [APP.
Several MME promoter polymorphisms have been associated with AD risk in candidate gene studies, though results are inconsistent across populations. Genome-wide association studies have not identified MME as a significant locus, suggesting common NEP variants confer small effects on AD risk.
[Somatostatin[/proteins/[somatostatin-protein[/proteins/[somatostatin-protein[/proteins/[somatostatin-protein[/proteins/[somatostatin-protein--TEMP--/proteins)--FIX-- (SST), itself a NEP substrate, positively regulates NEP expression through somatostatin receptors (particularly SSTR4), establishing a feedforward regulatory loop. This axis has profound AD implications: SST expression declines markedly with aging in rodents, primates, and humans, reducing the tonic drive for NEP expression and thereby decreasing Abeta clearance capacity. Saito et al. (2005) proposed that aging-dependent SST reduction is a primary trigger for Abeta accumulation by suppressing NEP action, linking the well-documented SST deficit in AD [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- to amyloid pathology (Saito et al., 2005).
The MME gene contains CpG islands in its promoter region that are susceptible to DNA methylation-mediated silencing. Studies examining AD brain tissue have investigated whether hypermethylation of the NEP promoter contributes to reduced expression. Chen et al. (2018) analyzed NEP promoter methylation in AD and control brains and found that while methylation patterns vary across brain regions, the methylation status of the NEP promoter alone does not fully account for reduced expression in AD, suggesting that other epigenetic and transcriptional mechanisms contribute (Chen et al., 2018).
Histone deacetylase ([HDAC[/entities/[hdac-enzymes[/entities/[hdac-enzymes[/entities/[hdac-enzymes[/entities/[hdac-enzymes--TEMP--/entities)--FIX-- inhibitors such as trichostatin A and valproate can partially restore NEP expression in neuronal cell lines, indicating that histone acetylation state regulates NEP transcription. Additionally, the [APP[/genes/[app[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX-- intracellular domain (AICD), released during [gamma-secretase[/entities/[gamma-secretase[/entities/[gamma-secretase[/entities/[gamma-secretase[/entities/[gamma-secretase--TEMP--/entities)--FIX-- cleavage of [APP[/genes/[app[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX--, has been shown to bind the NEP promoter and drive its transcription. This creates a regulatory feedback loop in which [APP[/genes/[app[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX-- processing generates both [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- substrate and AICD, which can upregulate NEP expression.strate) and AICD (which upregulates NEP to degrade Abeta). In AD, this feedback may be disrupted as pathological [APP[/genes/[app[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX-- processing shifts toward amyloidogenic pathways (Nalivaeva et al., 2012).
Gene therapy using adeno-associated virus (AAV) vectors to deliver the NEP transgene to the brain has shown substantial preclinical success. Iwata et al. (2013) demonstrated that a single intracardiac administration of AAV9-NEP in AD model mice achieved widespread neuronal NEP expression, reduced Abeta oligomers and plaque burden, and rescued learning and memory deficits. Carty et al. (2013) confirmed that intracranial AAV-NEP, but not AAV-[IDE[/genes/[ide[/genes/[ide[/genes/[ide[/genes/[ide--TEMP--/genes)--FIX--, significantly reduced amyloid pathology in [APP[/genes/[app[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX--; Carty et al., 2013).
The "peripheral sink" hypothesis proposes that reducing peripheral Abeta levels could create a concentration gradient favoring efflux of brain Abeta across the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- (BBB). Liu et al. (2010) showed that peripheral NEP expression via bone marrow transplantation reduced soluble brain Abeta by ~30% and insoluble Abeta by 50-60% (Liu et al., 2010). However, Walker et al. (2013) found that intravenous NEP efficiently cleared plasma Abeta but did not reduce brain Abeta over 3 months, challenging the peripheral sink concept (Walker et al., 2013).
More recent work has focused on [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX---penetrating NEP. Meier et al. (2022) engineered a soluble NEP fused to a transferrin receptor-targeting antibody fragment (sNEP-scFc-scFv8D3) that achieved 20-fold higher brain uptake after intravenous injection and reduced brain Abeta oligomers and monomers in AD mice (Meier et al., 2022).
Key obstacles for NEP-based strategies include: substrate promiscuity (global NEP enhancement would affect enkephalins, natriuretic peptides, and other bioactive peptides); [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- penetration (NEP does not cross the [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- natively); and timing, as NEP enhancement may be most effective before extensive Abeta aggregation into protease-resistant plaques.
The study of Neprilysin (Nep) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.